8-K: Gyre Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results, Provides Business Update, and Issues 2025 Revenue Guidance
Earnings Release
Gyre Therapeutics reports its Q4 and full year 2024 financial results, highlighting upcoming milestones including Phase 3 trial data and commercial launches, with a revenue guidance of $118 to $128 million for 2025.
Summary
- Gyre Therapeutics announced its financial results for the fourth quarter and full year ended December 31, 2024.
- The company anticipates a pivotal year in 2025 with expansion of commercial product offerings and clinical trial updates.
- Full year 2024 revenue was $105.8 million, compared to $113.5 million in 2023.
- The company expects to report topline data from its pivotal Phase 3 trial in CHB-associated liver fibrosis in Q2 2025.
- Gyre plans to initiate a Phase 2 clinical trial in MASH-associated liver fibrosis in the U.S. in 2025.
- The company expects full year 2025 total revenue to be between $118 and $128 million.
- As of December 31, 2024, Gyre had $51.2 million in cash, cash equivalents, short-term and long-term bank deposits.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive due to the expected revenue growth, new product launches, and progress in clinical trials, although tempered by the decrease in revenue in 2024 and increased operating expenses.
Positives
- Gyre plans to launch nintedanib and avatrombopag in the PRC in 2025, expanding its commercial product offerings.
- The company expects topline data from its Phase 3 trial in CHB-associated liver fibrosis in Q2 2025.
- Gyre plans to initiate a Phase 2 clinical trial in MASH-associated liver fibrosis in the U.S. in 2025.
- Gyre's income from operations for the full year 2024 was $16.2 million, compared to a $67.2 million loss in 2023.
- Net income for the full year 2024 was $17.9 million, compared to a net loss of $85.5 million in 2023.
Negatives
- Full year 2024 revenue decreased to $105.8 million from $113.5 million in 2023, primarily due to decreased sales of ETUARY and generic drugs.
- Non-GAAP adjusted net income for the full year 2024 decreased to $16.9 million from $25.4 million in 2023.
Risks
- The company's future revenue growth is dependent on the successful commercial launch of new products and sales of ETUARY.
- Fluctuations in the Chinese economy and healthcare spending could affect demand for anti-fibrosis drugs.
- Clinical trial results may not be positive or lead to regulatory approvals.
- Competition from other products could impact Gyre's market share and revenue.
Future Outlook
Gyre Therapeutics anticipates revenue between $118 and $128 million for full year 2025, driven by commercial launches of nintedanib and avatrombopag and sales of ETUARY.
Management Comments
- Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics, stated that 2025 is shaping up to be a pivotal year for Gyre.
- Han Ying expressed confidence in the company's ability to successfully launch and expand nintedanib and avatrombopag in the PRC.
Industry Context
Gyre's focus on organ fibrosis and its pipeline of drugs targeting liver diseases like CHB and MASH positions it in a growing market with significant unmet needs. The commercialization of generic nintedanib puts them in competition with other pharmaceutical companies in the IPF space.
Comparison to Industry Standards
- Gyre's ETUARY (Pirfenidone) competes with other IPF treatments like Esbriet (Pirfenidone) by Roche and Ofev (Nintedanib) by Boehringer Ingelheim.
- The company's focus on developing treatments for MASH-associated liver fibrosis aligns with the industry's increasing attention to this disease, with companies like Intercept Pharmaceuticals and Madrigal Pharmaceuticals also developing therapies in this area.
- Gyre's revenue guidance of $118 to $128 million for 2025 will be compared to the revenue growth of its competitors in the anti-fibrotic drug market.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Lead Independent Director | N/A | Ping Zhang | January 2025 | Appointment |
| Chairman and member of the Board of Directors of Gyre and Gyre Pharmaceuticals | Ying Luo, Ph.D. | Songjiang Ma (Chairman of the Board of Directors of Gyre Pharmaceuticals) | January 2025 | Resignation to focus on other responsibilities at GNI Group Ltd. |
Stakeholder Impact
- Shareholders may be impacted by the expected revenue growth and clinical trial results.
- Employees may be affected by the company's expansion and new product launches.
- Patients could benefit from the development and commercialization of new treatments for liver fibrosis and other diseases.
Next Steps
- Report topline data from the Phase 3 trial in CHB-associated liver fibrosis in Q2 2025.
- Initiate commercialization of nintedanib and avatrombopag in the PRC in 2025.
- Initiate a Phase 2 clinical trial in MASH-associated liver fibrosis in the U.S. in 2025.
- Complete the Phase 2 clinical trial of F573 as a treatment for ALF/ACLF by the end of 2026.
- Submit an IND application for F528 in COPD in 2026.
- Begin a Phase 1 trial of F230 for the treatment of PAH in 2025.
Key Dates
| Date | Description |
|---|---|
| March 2021 | F351 received Breakthrough Therapy designation by the NMPA Center for Drug Evaluation. |
| May 2024 | Gyre Pharmaceuticals executed an agreement for nintedanib. |
| June 2024 | Gyre Pharmaceuticals received approval for avatrombopag maleate tablets. |
| October 2024 | Last patient completed the 52-week pivotal Phase 3 trial of F351 in CHB-associated liver fibrosis. |
| December 31, 2024 | End of the reported financial year. |
| January 2025 | Ping Zhang appointed to the Board of Directors; Ying Luo resigned as Chairman. |
| March 17, 2025 | Date of the press release announcing financial results. |
| Q2 2025 | Expected topline data from Phase 3 trial in CHB-associated liver fibrosis. |
| 2025 | Expected commercial launch of nintedanib and avatrombopag in the PRC. |
| 2025 | Planned initiation of U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis. |
| End of 2026 | Expected completion of the Phase 2 clinical trial of F573 as a treatment for ALF/ACLF. |
Keywords
Gyre Therapeutics, financial results, liver fibrosis, F351, ETUARY, nintedanib, avatrombopag, MASH, CHB, clinical trial, revenue guidance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.